SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 22, 2004
ANTARES PHARMA, INC.
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
|(Commission File Number)|| |
707 Eagleview Boulevard, Suite 414, Exton, PA 19341
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (610) 458-6200
(Former Name or Former Address, if Changed Since Last Report)
Item 9. Regulation FD Disclosure.
Antares Pharma, Inc. (the Company) today made a presentation at its Annual Meeting of Shareholders regarding its operations and business. The PowerPoint slide presentation used during the Companys presentation at its Annual Meeting of Shareholders is furnished as Exhibit 99.1
The information in this Item 9 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended.
Item 7. Financial Statements and Exhibits.
|99.1||PowerPoint Slides (furnished)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: June 22, 2004||ANTARES PHARMA, INC.|
/s/ Lawrence M. Christian
|Lawrence M. Christian|
|Chief Financial Officer|